Aldoketo reductase inhibitors and uses thereof
An aldoketo reductase inhibitor includes a xanthene analogue.
1. A method of increasing S-nitrosylation of proteins in a subject in need thereof, the method comprising: administering to the subject a compound having the following formula:
or a pharmaceutically acceptable salt or tautomer thereof,
wherein R 1 , R 2 , R 3 , and R 4 are each independently H, a halo group, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylsulfide, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, —CF 3 , —S—CF 3 , —SO 2 CF 3 , CO—N(R a )—R b , C 1 -C 6 alkyl alcohol, C 1 -C 6 alkyl ether, nitro, C 1 -C 6 alkyl sulfide C 1 -C 6 alkyl, C 1 -C 6 alkylamine, C 1 -C 6 alkyl esters, carboxylic acids, C 1 -C 6 cycloalkyl, or C 1 -C 6 heterocyclyl, R a and R b are each independently H or a C 1 -C 6 alkyl, wherein at least one of R 1 , R 2 , R 3 , and R 4 is not H, wherein the compound is administered to the subject at an amount effective to increase S-nitrosylation of proteins in the subject.
2. The method of claim 1 , the subject-having a disorder associated with NO/SNO deficiency or those benefiting from increased SNO in a subject.
3. The method of claim 1 , the compound being administered at an amount effective to increase SNO levels in blood or tissue of the subject.
4. The method of claim 2 , wherein the disorder comprises ischemia.
5. The method of claim 4 , wherein the ischemia comprises ischemic tissue or tissue damaged by ischemia.
6. The method of claim 2 , the disorder comprising at least one of acute coronary syndrome, acute lung injury (ALI), acute myocardial infarction (AMI), acute respiratory distress syndrome (ARDS), arterial occlusive disease, arteriosclerosis, articular cartilage defect, aseptic systemic inflammation, atherosclerotic cardiovascular disease, autoimmune disease, bone fracture, bone fracture, brain edema, brain hypoperfusion, Buerger's disease, burns, cancer, cardiovascular disease, cartilage damage, cerebral infarct, cerebral ischemia, cerebral stroke, cerebrovascular disease, chemotherapy-induced neuropathy, chronic infection, chronic mesenteric ischemia, claudication, congestive heart failure, connective tissue damage, contusion, coronary artery disease (CAD), critical limb ischemia (CLI), Crohn's disease, deep vein thrombosis, deep wound, delayed ulcer healing, delayed wound-healing, diabetes (type I and type II), diabetic neuropathy, diabetes induced ischemia, disseminated intravascular coagulation (DIC), embolic brain ischemia, graft-versus-host disease, frostbite, hereditary hemorrhagic telengiectasia, ischemic vascular disease, hyperoxic injury, hypoxia, inflammation, inflammatory bowel disease, inflammatory disease, injured tendons, intermittent claudication, intestinal ischemia, ischemia, ischemic brain disease, ischemic heart disease, ischemic peripheral vascular disease, ischemic placenta, ischemic renal disease, ischemic vascular disease, ischemic-reperfusion injury, laceration, left main coronary artery disease, limb ischemia, lower extremity ischemia, myocardial infarction, myocardial ischemia, organ ischemia, osteoarthritis, osteoporosis, osteosarcoma, Parkinson's, Alzheimer's disease, or other neurodegenerative disease, peripheral arterial disease (PAD), peripheral artery disease, peripheral ischemia, peripheral neuropathy, peripheral vascular disease, pre-cancer, pulmonary edema, pulmonary embolism, remodeling disorder, renal ischemia, retinal ischemia, retinopathy, sepsis, skin ulcers, solid organ transplantation, spinal cord injury, stroke, subchondral-bone cyst, thrombosis, thrombotic brain ischemia, tissue ischemia, transient ischemic attack (TIA), traumatic brain injury, ulcerative colitis, vascular disease of the kidney, vascular inflammatory conditions, von Hippel-Lindau syndrome, liver injury, or wounds to tissues, skin, or organs.
7. The method of claim 1 , wherein at least one of R 1 , R 2 , R 3 , or R 4 is fluorine.
8. The method of claim 1 , the compound having the following formula:
or a pharmaceutically acceptable salt or tautomer thereof,
wherein R 1 , R 2 , R 3 , and R 4 are each independently H, a halo group, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylsulfide, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, —CF 3 , —S—CF 3 , —SO 2 CF 3 , CO—N(R a )—R b , C 1 -C 6 alkyl alcohol, C 1 -C 6 alkyl ether, nitro, C 1 -C 6 alkyl sulfide, C 1 -C 6 alkylamine, C 1 -C 6 alkyl esters, carboxylic acids, C 1 -C 6 cycloalkyl, or C 1 -C 6 heterocyclyl, R a and R b are each independently H or a C 1 -C 6 alkyl, wherein at least one of R 1 , R 2 , R 3 , and R 4 is not H.
9. The method of claim 1 , wherein at least one of R 1 , R 2 , R 3 , or R 4 is fluorine.
10. The method of claim 9 , the compound having the following formula:
or a pharmaceutically acceptable salt or tautomer thereof.
11. The method of claim 1 , the compound having the following formula:
or a pharmaceutically acceptable salt or tautomer thereof.
12. The method of claim 1 , the compound having a AKR1A1 to AKR1B1 inhibitor selectivity (AKR1A1/AKR1B1) of at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, or more.